ArticleBlood advances2019
A role for IL-34 in osteolytic disease of multiple myeloma.
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- IL-34 Regulates Macrophage Polarization and Bone Defect Healing in Aged Mice.International journal of molecular sciences · 2026Article
- Role of IL-34 in Tumors and Its Application to Regulate Inflammation.Cancer science · 2025Review
- Impact of myosteatosis on prognosis in multiple myeloma patients: A subgroup analysis of 182 cases and development of a nomogram.Journal of bone oncology · 2025Article
- IL-38 as a Novel Biomarker in Multiple Myeloma Patients: A Prospective Clinical Evaluation.Cancer management and research · 2025Article
- Effects of IL-34 and anti-IL-34 neutralizing mAb on alveolar bone loss in a ligature-induced model of periodontitis.Molecular oral microbiology · 2024Article
- Elevated circulating levels of IL-34 are strongly associated with osteoporosis.Archives of osteoporosis · 2023Article
- Extracellular Signal-Regulated Kinases Play Essential but Contrasting Roles in Osteoclast Differentiation.International journal of molecular sciences · 2023Review
- Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents.Journal of bone and mineral metabolism · 2023Review
- Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance.Cancers · 2023Review
- Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer.Frontiers in oncology · 2023Review
- CSF1R as a Therapeutic Target in Bone Diseases: Obvious but Not so Simple.Current osteoporosis reports · 2022Review
- Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells.World journal of gastrointestinal oncology · 2022Article
- IL-34 Aggravates Steroid-Induced Osteonecrosis of the Femoral Head via Promoting Osteoclast Differentiation.Immune network · 2022Article
- IL-34 in hepatoblastoma cells potentially promote tumor progression via autocrine and paracrine mechanisms.Cancer medicine · 2022Article
- Interleukin-34 promotes tumorigenic signals for colon cancer cells.Cell death discovery · 2021Review
- IL-34 affects fibroblast-like synoviocyte proliferation, apoptosis and function by regulating IL-17.Scientific reports · 2021Article
- The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis.Theranostics · 2021Review
- Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.Frontiers in immunology · 2021Review
- Article
- The M-CSF receptor in osteoclasts and beyond.Experimental & molecular medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a hematological malignancy that grows in multiple sites of the axial skeleton and causes debilitating osteolytic disease. Interleukin-34 (IL-34) is a newly discovered cytokine that acts as a ligand of colony-stimulating factor-1 (CSF-1) receptor and can replace CSF-1 for osteoclast differentiation. In this study, we identify IL-34 as an osteoclastogenic cytokine that accelerates osteolytic disease in MM. IL-34 was found to be expressed in the murine MM cell line MOPC315.BM, and the expression of IL-34 was enhanced by stimulation with proinflammatory cytokines or by bone marrow (BM) stromal cells. MM-cell-derived IL-34 promoted osteoclast formation from mouse BM cells in vitro. Targeting
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.